Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
Holding NEO?
Track your performance easily
NEO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.77 - $21.22
Previous Close$15.36
Volume398.69K
Average Volume (3M)740.39K
Market Cap
$1.97B
Enterprise Value$2.19B
Total Cash (Recent Filing)$387.81M
Total Debt (Recent Filing)$606.27M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Feb 25, 2025EPS Estimate
$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding128,360,871
10 Day Avg. Volume774,054
30 Day Avg. Volume740,386
Standard Deviation0.17
R-Squared0.14
Alpha-0.00899
Financial Highlights & Ratios
Price to Book (P/B)2.17
Price to Sales (P/S)3.00
Price to Cash Flow (P/CF)52.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.40
Enterprise Value/Gross Profit8.95
Enterprise Value/Ebitda5.42K
Forecast
1Y Price Target
$20.57Price Target Upside33.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
NeoGenomics News
PremiumCompany Announcements
NeoGenomics Reports Strong Q3 2024 Growth
PremiumCompany Announcements
NeoGenomics Reports Strong Q3 2024 Revenue Growth
PremiumPre-Earnings
Is NEO a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
EarningsThe company's clinical testing segment saw revenues slightly ahead of consensus and a 14% increase year-over-year, driven by an increase in the average unit price and a push on reimbursement initiatives.
Financial PerformanceGross margin benefited from investments in productivity and automation, reaching 47.8%, slightly ahead of consensus expectations.
Growth OpportunitiesNeoGenomics Inc. is viewed as a one-stop oncology lab testing service provider with growth opportunities in NGS products and biopharma Dx services.
Bears Say
Financial PerformancePharma Advanced Dx business was softer than expected, missing Street expectations by 10% due to an unimproved biotech/biopharma backdrop.
Legal ChallengesThe RaDaR injunction remains an overhang on the stock, affecting its performance.
Revenue GrowthRevenue growth slowed to 10% in 3Q24 from 12% in 2Q24, driven by slower Advanced Diagnostics growth.
---
Ownership Overview
1.16% Insiders
36.46% Mutual Funds
23.41% Other Institutional Investors
13.31% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $12.77 and its highest was $21.22 in the past 12 months.
What is NeoGenomics’s market cap?
Currently, no data Available
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Feb 25, 2025 which is in 96 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Nov 05, 2024. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.012 by $0.038.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is $0.03.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 128,360,870 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.05 in its last earnings report, beating expectations of $0.012. Following the earnings report the stock price went up 5.587%.
Which hedge fund is a major shareholder of NeoGenomics?
Among the largest hedge funds holding NeoGenomics’s share is Royce & Associates LLC. It holds NeoGenomics’s shares valued at 9M.
---
NeoGenomics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.57 (33.92% Upside)
$20.57 (33.92% Upside)
Hedge Fund Trend
Increased
By 19.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 16.4%
Last 30 Days ▲ 27.8%
Last 30 Days ▲ 27.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.86%
12-Months-Change
Fundamentals
Return on Equity
-8.38%
Trailing 12-Months
Asset Growth
-2.21%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
---
NEO Company Deck
---
NEO Earnings Call
Q3 2024
0:00 / 0:00
---
NEO Stock 12 Month Forecast
Average Price Target
$20.57
▲(33.92% Upside)
Technical Analysis
Best Analysts Covering NEO
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+4.70%
assigned a buy rating 15 days ago
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +4.70% per trade.
---